These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24935915)

  • 1. A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials.
    DeSantis SM; Zhu H
    Med Decis Making; 2014 Oct; 34(7):899-910. PubMed ID: 24935915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
    Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
    Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
    Klemperer EM; Hughes JR; Naud S
    Drug Alcohol Depend; 2018 Sep; 190():229-234. PubMed ID: 30059816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
    Bouza C; Angeles M; Muñoz A; Amate JM
    Addiction; 2004 Jul; 99(7):811-28. PubMed ID: 15200577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.
    Mason BJ
    Eur Neuropsychopharmacol; 2003 Dec; 13(6):469-75. PubMed ID: 14636963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
    Petrov I; Krogh J; Nordentoft M
    Ugeskr Laeger; 2011 Nov; 173(48):3103-9. PubMed ID: 22118653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acamprosate for the treatment of alcohol dependence.
    Boothby LA; Doering PL
    Clin Ther; 2005 Jun; 27(6):695-714. PubMed ID: 16117977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
    Soyka M; Chick J
    Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.
    Litten RZ; Castle IJ; Falk D; Ryan M; Fertig J; Chen CM; Yi HY
    Alcohol Clin Exp Res; 2013 Dec; 37(12):2128-37. PubMed ID: 23889231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
    Mason BJ
    J Stud Alcohol Suppl; 2005 Jul; (15):148-56; discussion 140. PubMed ID: 16223066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
    Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
    Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
    Snyder JL; Bowers TG
    Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment of alcohol dependence: a review of the evidence.
    Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
    JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
    Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
    Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
    Falk D; Wang XQ; Liu L; Fertig J; Mattson M; Ryan M; Johnson B; Stout R; Litten RZ
    Alcohol Clin Exp Res; 2010 Dec; 34(12):2022-34. PubMed ID: 20659066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the pharmacotherapy of alcoholism.
    Myrick H; Anton R
    Curr Psychiatry Rep; 2004 Oct; 6(5):332-8. PubMed ID: 15355755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pharmacotherapies for alcohol dependence.
    Graham R; Wodak AD; Whelan G
    Med J Aust; 2002 Jul; 177(2):103-7. PubMed ID: 12098353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data.
    Mason BJ; Lehert P
    Alcohol Clin Exp Res; 2012 Mar; 36(3):497-508. PubMed ID: 21895717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
    Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
    Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
    Rösner S; Leucht S; Lehert P; Soyka M
    J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.